Please ensure Javascript is enabled for purposes of website accessibility

Becton, Dickinson Wins Designation Allowing European Sales of Coronavirus Test

By Eric Volkman – Oct 2, 2020 at 10:32AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This comes less than three months after the company received an emergency use authorization for the test from the FDA.

Earlier this week, Becton, Dickinson (BDX 0.67%) revealed that it has been given a crucial new green light to market its rapid test for the detection of the novel coronavirus. The healthcare technology specialist has been awarded a CE Mark for its SARS-CoV-2 assay, meaning it can be sold throughout Europe in countries that support the quality designation.

According to Becton, Dickinson, its SARS-CoV-2 antibody test produces results in 15 minutes. It is processed using the BD Veritor Plus System, a handheld and portable device used for various diagnostics that can be administered where the test subject is situated. The device already carries a CE Mark.

Becton Dickinson's BD Veritor Plus device.

Image source: Becton, Dickinson.

"The addition of a truly portable, point-of-care test that can deliver results while the patient waits will be welcomed by healthcare providers and patients alike to help protect against additional waves of COVID-19," said Roland Goette, the company's Europe, Middle East and Asia (EMEA) region president, in a press release.

Becton, Dickinson added that it is tapping its worldwide manufacturing network to make 8 million of the coronavirus tests per month. It expects to be able to increase production to 12 million per month by March.

When the test was awarded an emergency use authorization by the FDA back in July, Becton, Dickinson noted that the BD Veritor Plus System was already being used in more than 25,000 U.S. healthcare facilities to process tests that detect other illnesses.

The number of new coronavirus cases has been on the rise -- sometimes sharply -- in locales across Europe during the past few weeks. Therefore, the need for a reliable test that can be moved where needed, and produce results relatively quickly, remains acute there.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Becton, Dickinson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Becton, Dickinson Stock Quote
Becton, Dickinson
$238.94 (0.67%) $1.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.